Advances in muc1‐mediated breast cancer immunotherapy research center of clinical medicine jiangsu taizhou people’s hospital (affiliated hospital of nantong

HIGHLIGHTS

• who: Admin from the Currently, CAR T‐cell therapy is becoming a rapidly developing and extensively used antitumor cell immunotherapy branchAt present, it substantially alters the hema‐ tological malignancy landscape, occupying over half of the developing or the already‐ used cell treatments [118]. However, there were still problems associated with the use of CAR T‐cells in treating solid tumors, regardless of its successful treatment of hematolog‐ ical cancers [119, ]. Typically, CAR T‐cell therapy, when it is used in treating solid tu‐ mors, is associated with the primary challenge of identifying suitable tumor target anti‐ gens . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.